BC
VKTX icon

Bridgefront Capital’s Viking Therapeutics VKTX Stock Holding History

Bridgefront Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
+12,347
New +$399K 0.13% 267
2026
Q1 		– Sell
-7,289
Closed -$256K – 772
2025
Q4 		$256K Sell
7,289
-1,606
-18% -$56.9K 0.06% 405
2025
Q3 		$234K Buy
+8,895
New +$265K 0.07% 475

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bridgefront Capital's VKTX Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 12,347 shares worth $482K. The stake represents 0.13% of the portfolio and ranks #267 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in VKTX as recently as Q4 2025.

Bridgefront Capital first reported a position in VKTX in Q3 2025 and has held it in 3 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Bridgefront Capital held 12,347 shares of Viking Therapeutics worth $482K as of Q2 2026.
  • Viking Therapeutics was a new Bridgefront Capital position in Q2 2026.
  • Viking Therapeutics made up 0.13% of Bridgefront Capital's portfolio in Q2 2026, its #267 holding.
  • Bridgefront Capital first reported a position in Viking Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.